european journal
of gynaecological oncology
an International Journal
| Editors-in-Chief |
A. Onnis
Montréal (CND) |
P. Bösze
Budapest (Hungary) |
Associate Editors
| M. Marchetti |
| Montréal (CND) |
Assistant Editor
J. Wilson
San Diego - CA (USA)
| Editorial Board |
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Barber H.K., New York, NY (USA)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Fuller A.F. Jr., Boston, MA (USA) |
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M., Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,Athens (Greece)
Jordan J.A., Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Kudelka A.P., Houston, TX (USA)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G., |
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H., London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Vîrtej P., Bucharest (Romania)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan) |
Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal,
Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com
- www.irog.net
Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 -
Fax (39) 049 8752018
|
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN
0392-2936) publishes original peer reviewed works in the fields of female
genital cancers and related subjects and also proceedings of gynecologic
oncology society meetings all over the world. The Journal is covered by
CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/
Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.
European Journal of Gynaecological
Oncology
www.irog.net
General Information
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936)
publishes original peer reviewed work, preferably brief reports, in the
fields of female genital cancers and related subjects – prevention,
early detection, epidemiology, pathology, diagnosis, management –
and also proceedings of Gynaecologic Oncology Society meetings all over
the world.
The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT,
INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.
AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing
editorial articles in the “Distin-guished Expert Series” and
original research papers, case reports, letters to the Editor, book reviews
and newsletters.
The Journal was founded in 1980 – the second gynaecologic oncology
hyperspecialization journal in the world. Its aim is the dif-fusion of
scientific, clinical and practical progress and knowledge in female neoplastic
diseases in an interdisciplinary approach among gynaecologists, oncologists,
radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists
and so on.
ANNOUNCEMENTS regarding meetings, postgraduate courses
and symposia will be accepted 6 months before publication and will be
published free of charge.
BOOK SAMPLES for review should be sent to the Editorial
offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright
Clearance Center, Inc. Reproductions are not allowed without the written
consent of the Publisher. All photocopy fees should be paid to the Copyright
Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating
the ISSN number, the volume and the first and last page numbers of each
article copied.
ADVERTISING INFORMATION: advertising orders and inquiries
may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc,
Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640
- Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the
editorial staff and the printer to eliminate misleading or inaccurate
infor-mation, the publisher accepts no responsibility for the consequences
of faultful or incorrect information. The authors recognize that the editor
and publisher have no responsibility and are indemnified against any liability
or claim that may result from the publication of misleading or incorrect
data.
SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September
and November); one volume per year. Subscriptions start from January and
are automatically renewed if not cancelled by the end of September.
Subscriptions include six issues per year plus supplements, monographs
and all official communications of Meetings, Courses, Symposia and all
scientific activities of Gynaecologic Oncology Societies all over the
world.
Subscriptions are entered with prepayment only. The annual
subscription is $390 US for Institutions, $200 US for Individuals. For
airmail add $30, for receipt add $10 US. Single copy prepaid cost $95
US.
Send subscription requests with cheque or credit card payment (Amex -
Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte
St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only
US Funds are accepted. No bank transfers.
Claims for missing issues can be honoured up to six months.
Changes of address: allow six weeks for all changes to
become effec-tive. All communications should include both old and new
addresses (with postal codes) – better if accompanied by a mailing
label from a recent issue – and should be sent to the printer: La
Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580.
Claims should be made within six months of publication date.
Duplicate copies will not be sent to replace those undelivered through
failure to notify of change of address.
Single copies and back issue and volume information is available from
the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580.
Certain back issues may only be available as photocopies of the originals.
All other business correspondence including orders for offprints and advertising
space and any communication and requests should be addressed to I.R.O.G.
CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC
H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.
IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT
European Journal of Gynaecological
Oncology
www.irog.net
Instructions to Authors
SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN
JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212
MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513,
or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.
Editorial articles for publication in the “Distinguished Expert
Series” should be submitted to P. Bösze, Editor-in-Chief of
this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest,
Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu
When a manuscript is submitted, an acknowledgement card is sent to the
corresponding author within two or three weeks.
Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees.
Authors may be required to modify the manuscript according to the reviewers’
suggestions.
Manuscripts accepted for publication will be copyedited by the editorial
staff for typographical and grammatical mistakes and to guarantee clarity
and conciseness.
Publication time will be the shortest possible based
on scientific and publishing needs. Manuscripts submitted for
publi-cation cannot be returned.
Published papers will become property of the Journal and copyrighted under
I.R.O.G. CANADA Inc.
After six months no grievances will be accepted regarding published articles.
All statements are the responsibility of the authors. Product dosages,
indications and methods referred to in the papers reflect the author’s
experience. No responsibility is assumed by the Editor-in-Chief or the
Publisher for any damage from use of any products, operation methods or
instructions contained in the published materials.
Trade names, trademarks, etc. are protected by the law and regulations.
The Editor-in-Chief and the Publisher cannot accept any legal responsibility
for any errors or omissions that may be made in press, particularly for
information about drug dosage and appli-cation thereof contained in the
Journal. Consult the prescribing information before administering any
drug.
MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted
to biomedical journals” published in the New England Journal of
Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.
Three manuscripts, typed and double spaced should be
submitted with an electronic disk, formatted in Word for Macintosh
or Windows, version 6.0. Manuscripts without an electronic disk
will not be accepted. A cover letter signed by all authors must
state that all authors who have participated in the work take responsibility
for the manuscript which has never been pub lished or submitted for publication
elsewhere. Without a cover letter the publication will not be
possible. Name, address and phone/fax numbers of the Corresponding Author,
responsible for revision and approval of the proofs, should be indicated.
Full-length articles should not exceed 8 printed pages including tables
and references.
After the title page (full title and names of authors,
institutions, eventual acknowledgement for financial support, running
title of no more than 60 characters or spaces), original works should
be arranged in the conventional order: Summary (purpose of investiga-tion,
methods, results, conclusion - about 150 words), Key words, Content
(a 20-word summary), Introduction, Materials and Methods, Results,
Discussion, Conclusion, Acknowledgement (if any), References, Tables,
Legends.
Authors should supply a complete address for reprint requests.
In the text only standard abbreviations can be used and must be avoided
in the title. The full term for which an abbreviation stands should precede
its first use in the summary and text unless it is a standard unit of
measurement.
Authors must give their complete professional identifications
and affiliations, including all academic titles and positions.
Letters to the editor should be brief (500 words or less)
and offer objective, constructive and educational criticism of published
material. The editor reserves the right to publish.
Figures: Two original copies (not negatives) of each
figure are requested. Each figure should have a label on the back indicating
its number, author’s name and top of the figure. Do not write on
the back of the figures and do not mount them on cardboard. If
sending colour pictures advise if they must be printed in colour or black
and white (colour costs ten times more).
Legends should be typed on a separate page with Arabic
numerals corresponding to the illustrations.
Tables should be titled, typed in double space on separate
pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood
abbreviations should be used.
References should be numbered consecutively in the order in which
they are first mentioned in the text. Identify references in
the text, tables, and legends by Arabic numerals in parentheses.
Use the style of the examples below, which are based with slight modifications
on the format used by the U.S. National Library of Medicine in Index Medicus.
The titles of journals should be abbreviated according to the style used
in Index Medicus.
References must be verified by the Author(s) against the original documents.
Examples of correct forms of references are given below:
Articles in Journals: Authors’ surname and initials
(if more than six names, give six followed by “et al.”), Title,
Abbreviated Journal Title, Year of Publication, Volume, Issue and first
page.
Books: Authors’ surname and initials, title of
the book and title of chapter, in: Title, Editor(s), Place, Publisher,
Year, Page.
Acknowledgments will be limited to appropriate professionals
who were contributors to the paper.
PROOFS revised by the editorial staff will
be sent to the corresponding author and should be checked and returned
within ten days. The corresponding author is responsible for detecting
typesetting errors. After this deadline the proofs will be considered
approved. Only essential corrections should be made; extensive changes
will be charged to the authors.
BUSINESS MATTERS
The Journal has no commercial advertisements.
Authors will be expected to contribute to the printing expenses,
tables, figures and postage. For every published article a copy
of the Journal will be provided free of charge. Only payments
in US dollars will be accepted. No bank transfers.
Reprints should be requested with the form enclosed
with the acceptance letter. No free reprints will be supplied.
© By I.R.O.G. CANADA INC. - Publisher - Editorial office
4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3
(Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy
by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy)
- Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s
Court n. 633 - 28-6-1979 |
| |
|
 European Journal of Gynaecological Oncology - Vol. XXVIII, n. 6, 2007 |
|
| |
|
| CONTENTS |
|
| DISTINGUISHED EXPERT SERIES |
|
| Current direction in the prevention of cervical cancer |
433 |
J. Monsonego - Paris, FRANCE
In the prevention of cervical cancer the vaccines against papillomavirus have a high efficacy; these prophylactic vaccines protect
women against precancerous and cancerous lesions associated with HPV. |
|
 |
|
| REVIEW ARTICLE |
|
| Management of recurrent cervical cancer. Review of the literature and case report |
435 |
Ph. Elst, F. Ahankour,W. Tjalma - Edegem, BELGIUM
A case of complete response after chemotherapy for recurrent cervical cancer is reported together with classification design
and flow-chart for the management of recurrent cervical cancer. |
|
 |
|
| ORIGINAL ARTICLES |
|
| Genetic imbalance and human papillomavirus states in vulvar squamous cell carcinomas |
442 |
O. Yangling, Z. Shulang, C. Rongoli, L. Bo, C. Lili,W. Xin - Shenyang, CHINA
Oncogenes located on 3q and 12q are important in the development and progression of HPV-induced carcinomas. |
|
| Primary chemotherapy with sequential docetaxel followed by docetaxel and epirubicin in large operable breast cancer |
447 |
C. Frutuoso, I. Henriques, I. Pazos, E. Abraul, A. Pego, J. Belo, O. Campos, H. Gervásio, C. de Oliveira -
Coimbra, PORTUGAL
Sixty-five patients with operable breast cancer were submitted to primary chemotherapy with sequential docetaxel followed by
epirubicin and docetaxel in order to evaluate conservative breast surgery and pathological response. |
|
| Comparison of the molecular classification with FIGO stage and histological grade on endometrial cancer |
451 |
B. Cai, L. Liu, X. W. Xi,Y. P. Zhu, G. Z. Lu,Y. X. Yang, X. P. Wan - Shanghai, CHINA
To compare the prognostic value of classification based on gene expression profiling, grade, and stage on endometrial cancer. |
|
Influence of the management of cervical carcinoma on the activity of catalase and glutathione peroxidase
in erythrocytes |
461 |
B. Woz´niak, C. Mila-Kierzenkowska, K. Ke˛dziora-Kornatowska, T. Drewa, G. Drewa, A. Woz´niak, E.
Krzyz·yn´ska-Malinowska, R. Makarewicz - Bydgoszcz, POLAND
Recovery of CAT and GPx activity may prove treatment efficacy, however it is not dependent on treatment modality. |
|
Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian
serous carcinoma |
464 |
H. Chen, F. Ye, J. Zhang,W. Lu, Q. Cheng, X. Xie - Hangzhou, CHINA
Loss of OPCML expression occurs frequently in ovarian serous carcinoma. CpG island methylation and LOH appear to be two
mechanisms of OPCML inactivation. |
|
Urban-rural differences in gynaecological cancer occurrence in a central region of Italy: 1978-1982 and
1998-2002 |
468 |
L. Minelli, F. Stracci, T. Cassetti, A. Canosa, M. Scheibel, I.E. Sapia, C. Romagnoli, F. La Rosa - Perugia, Italy
Compliance to mass screening procedures in urban-rural regions influences occurrence of gynaecological cancers. |
|
| TV sonographic assessment in postmenopausal asymptomatic women |
473 |
P. Tsikouras, G. Galazios, V. Liberis, A. Bouzaki, X. Grapsas, G. Maroulis - Alexandroupolis, GREECE
Transvaginal sonography is an efficient and safe method for early detection of endometrial pathology in postmenopausal
asymptomatic women. |
|
Survival rate and prognostic factors for patients who underwent surgical procedures for invasive carcinoma
of the vulva in Serbia |
477 |
T. Bozanovic, A. Ljubic, P. Momcilov, S. Milicevic, T. Mostic, S. Petkovic - Belgrade,SERBIA
Five-year survival rate and prognostic factors for patients who underwent radical operations for carcinoma of the vulva were
studied. |
|
 |
|
| CASE REPORTS |
|
| Aggressive angiomyxoma: case report and review of the literature |
480 |
D.C. Tsarpalis, C.K. Giannakopoulos, A.A. Lagadas, E.G. Toufexi - Athens, GREECE
Aggressive angiomyxoma is a rare benign neoplasm of the female pelvis. Surgical excision is the treatment of choice and longterm
imaging follow-up of patients is necessary. |
|
| Low-grade endometrial stromal sarcoma of the endocervix. Report of a case and review of the literature |
483 |
D. Hasiakos, K. Papakonstantinou, A. Kondi-Paphiti, S. Fotiou - Athens, GREECE
A description of the clinical and pathological findings of a case of low-grade endometrial stromal sarcoma of the endocervix in
a 44-year-old woman and review of the literature are presented. The difficulties in differential diagnoses as well as the therapeutic
options are also discussed. |
|
Late recurrence of ovarian granulosa cell tumor at the retroperitoneal and renal hilum level in a singlekidney
patient - case report |
487 |
M.J. Donate-Moreno, H. Pastor-Navarro, P. Carrión-López, A. Pascual-Martín, A.S. Salinas-Sánchez, J.G.
Lorenzo-Romero, L; Polo-Ruiz, J.A. Virseda-Rodríguez - Albacete, SPAIN
A case of late recurrence of ovarian granulosa cell tumor at the renal hilium level in a single kidney patient is presented. |
|
A rare case of extra-adrenal pheochromocytoma masquerading as an ovarian mass treated by laparoscopic
surgery |
491 |
S. Montemurro, E. Ruggieri, E. Maselli, A.F. Zito, F. Chiumarulo, G. Gargano - Bari, ITALY
A rare case of a 48-year-old woman affected by an extra-adrenal pheochromocytoma simulating an ovarian tumor successfully
treated by laparoscopic resection is presented. |
|
| Two cases of post-radiation osteosarcoma of the sacrum after pelvic irradiation for uterine cervical cancer |
497 |
J.M. Noh, S.J. Huh - Seoul, KOREA
After pelvic radiotherapy for cervical cancer, post-radiation osteosarcoma can develop as a rare and serious long-term sequelae. |
|
Primary serous carcinoma of the fallopian tube with synchronous cervical epidermoid carcinoma in
situ: a case report |
501 |
S. Ayas, A. Karateke, I. Aköz, G. Kir, I. Yenidede - Istanbul, TURKEY
A case of synchronous tumors, serous carcinoma of the fallopian tube and in situ cervical cancer is described. |
|
| Surgical approach to appendiceal mucocele mimicking an adnexal complex mass: case report |
503 |
C. Scaffa, O. Di Bella, E. Tartaglia, M. Rotondi, F. Lup, E.M. Messalli - Naples, ITALY
A rare case of mucocele of the vermiform appendix mimicking an adnexal complex mass and the relative surgical options are
reported. |
|
Primary endodermal sinus tumor of the vulva in a 52-year-old woman with long-term survival: a case
report |
506 |
K. Niwa, K. Onogi,Y. Wu, H. Mori, T. Tamaya - Gifu-City, JAPAN
An extremely rare case of primary endodermal sinus tumor of the vulva in a 52-year-old woman is reported. |
|
| Giant bladder leiomyoma presenting as a pelvic mass: a case report |
509 |
E. Erdemoglu, M. Kamacı - Ankara, TURKEY
A rare case of bladder leiomyoma with an unusual presentation as a pelvic mass is reported. |
|
| Malignant mixed müllerian tumor of the fallopian tube coincident with a primary serous carcinoma of the ovary. Case report |
511 |
L. Nappi, U. Indraccolo, M. Matteo, P. Rosenberg, P. Greco - Foggia, ITALY
The coexistence of fallopian malignant mixed müllerian tumor and serous ovarian carcinoma may be difficult to manage after surgery. |
|
| Ascites, high CA-125 and chronic pelvic pain in an unusual clinical manifestation of Enterobius vermicularis ovarian and sigmoid colon granuloma |
513 |
M. Podgajski, V. Kukura, Z. Duic, S. Gasparov, M. Madzarac - Zagreb, CROATIA
Enterobius vermicularis infestation-related lesions can mimic signs and symptoms of gynecologic malignant disease. |
|
| Ovarian gonodoblastoma with yolk sac tumor in a young 46, XX female: case report |
516 |
E. Erdemoglu, S. Özen - Ankara, TURKEY
A case of a pure endodermal sinus tumor in the ovary with gonodoblastoma in a 46 XX adolescent female is presented. |
|
| Thecoma associated with pregnancy: a case report |
519 |
F.F. Yanık, E. Kus¸c¸u, D. Eroglu, I. Kahraman, B. Sürücü, A. Çolak - Ankara, TURKEY
A pregnant woman with a solid ovarian mass and ascites was operated on at the 19th gestational week. Diagnosis was a torsioned luteinized thecoma. |
|
| Primary lymphoma of the uterine corpus: An unusual location for a common disease - case report |
522 |
K. Niwa, K. Onogi,W. Yun,Y. Hirose, T. Tamaya - Gifu-City, JAPAN
A case of a primary uterine corpus lymphoma, diffuse large B-cell type, in a 75-year-old woman is described. |
|
| Does the copper intrauterine device affect serum cancer antigen 125 levels? |
524 |
M. Karaca, S. Kumru, N. Dikmeli - Elazig, TURKEY
The copper intrauterine device influences serum CA-125 levels. |
|
| Folate and vitamin B12 levels in abnormal pap smears: a case control study |
526 |
H. Yüksel, A.R. Odabasi, G. Çetin, M. Eben, S. Nergiz, E. Onur - Mugla, TURKEY
Lower serum vitamin B12 levels were associated with abnormal cervical cytology. |
|
| Primary fallopian tube carcinoma in a 51-year-old postmenopausal woman - case report |
531 |
M. Vasiljevic, V. Pazin, O. Dzatic, D. Jeremic - Belgrade, SERBIA
A rare case of primary adenosquamous cell carcinoma of the fallopian tube is reported. |
|
| |
|
| EXPERIMENTAL RESEARCH |
|
| The effects of anastrozole on neonatal rat skin |
534 |
C. Akcali, S. Inaloz, M. Karakok, O.C. Demirtas, N. Kirtak, S. Inaloz - Gaziantep, TURKEY
The effects of anastrozole administration were investigated on neonatal rat skin. |
|
 |
|
| Contents index vol. XXVIII, 2007 |
537 |
 |
|
| Authors index vol. XXVIII, 2007 |
545 |
 |
|
| ERRATA - CORRIGE |
|
Ovarian clear cell adenocarcinoma producing alpha-fetoprotein: case report
Vol. XXVIII, n. 3, 2007, page 241
Errata:
A. Cetin, Z. Bahat, P. Cikesiz, N. Demirbag˘, E. Yavuz - Istanbul, TURKEY
Corrige:
A. Cetin, Z. Bahat, P. Cilesiz, N. Demirbag˘, E. Yavuz - Istanbul, TURKEY |
|
|